Genetic Technologies is a leading-edge molecular testing business with over 20 years experience globally. The Company specializes in providing an extensive portfolio of genetic tests, including those addressing various aspects of cancer development, progression and management.
Genetic Technologies’ molecular tests provide personalized and actionable diagnostic results to patients and clinicians enabling them to make better informed choices and access to intervention strategies. Genetic Technologies provides accurate and rapid turnaround times.
Following the acquisition of BREVAGen™, a proprietary breast cancer risk assessment test, Genetic Technologies has established operations in the US enabling us to offer this exciting test in all 50 states.
Genetic Technologies’ headquarters is based in Melbourne, Australia, with a state-of-the art on site molecular laboratory which is CLIA and ISO standard accredited. Committed to the highest quality standards enables us to service both domestic and international markets, ensuring the most reliable and accurate laboratory testing and the provision of valuable information in a timely manner.
Listed on the ASX (GTG) and NASDAQ (GENE), Genetic Technologies has created a successful multi-faceted genetic testing business together with expertise in the intellectual property field. The Company partners with world leading suppliers, clinical researchers and academic collaborators.